RxDoctor Payments Data

Ishvari Panarker, MD

Family Medicine · Schaumburg, ILNPI 1629208129

Payments from drug & device makers

$878in general payments, 2019–2025

Across 30 payments — averaging $29.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Abbott$344
  • Lilly USA, LLC$250
  • Boehringer Ingelheim$60
  • GSK$52
  • Novo Nordisk$45
  • AstraZeneca$27
  • plus $100 from 5 others

What the payments were for

  • Food & beverage$878100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$878 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$81,911
Medicare patients
155
Services billed
1,022

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide24$43,987
JardianceEmpagliflozin17$23,640
OzempicSemaglutide17$21,058
Trelegy ElliptaFluticasone/Umeclidin/Vilanter18$15,293
Atorvastatin Calcium130$1,441
Levothyroxine Sodium100$1,423
Metoprolol Succinate53$1,349
Rosuvastatin Calcium129$1,276
Losartan Potassium105$1,153
Albuterol Sulfate HfaAlbuterol Sulfate26$1,025
Metformin Hcl ErMetformin Hcl48$648
Sertraline Hcl46$612
Montelukast Sodium37$612
Nifedipine ErNifedipine13$553
Lisinopril55$473

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$250$43,98724 claims
Boehringer IngelheimJardiance$60$23,64017 claims
Novo NordiskOzempic$45$21,05817 claims
GSKTrelegy Ellipta$52$15,29318 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Schaumburg

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →